{"id":"W4311621345","doi":"10.3390/curroncol29120778","title":"Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Ottawa Hospital; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Pertuzumab; Medicine; Trastuzumab; Breast cancer; Neoadjuvant therapy; Oncology; Internal medicine; Adverse effect; Chemotherapy; Stage (stratigraphy); Guideline; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00352756,0.0003051286,0.0005511259,0.001298605,0.005633229,0.003869819,0.001932154,0.003822344,0.007783924],"category_scores_gemma":[0.02145691,0.0002941385,0.0004940204,0.00227841,0.00425162,0.002689125,0.001931262,0.006750857,0.0006686199],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.05921686,"about_ca_system_score_gemma":0.1378714,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.961845,"about_ca_topic_score_gemma":0.9779926,"domain_scores_codex":[0.9955325,0.0006290836,0.0003781504,0.0004297708,0.00180879,0.00122174],"domain_scores_gemma":[0.9828896,0.00324425,0.001427688,0.0003180437,0.007601967,0.00451841],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002967126,0.0000948685,0.05032743,0.00110649,0.0001555801,0.008869956,0.004313065,0.001166701,0.001305446,0.07845896,0.6226355,0.2312692],"study_design_scores_gemma":[0.0001564315,0.0001016944,0.05671996,0.004609393,0.0002185956,0.008190023,0.0124981,0.002119437,0.0008749434,0.04850382,0.8656504,0.0003572352],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.009749567,0.02450092,0.0006950774,0.9414126,0.001498138,0.00003681905,0.0005898103,0.00003196019,0.02148523],"genre_scores_gemma":[0.4343403,0.09833804,0.005179827,0.4370126,0.006400498,0.0001195591,0.001223937,0.0002245604,0.01716069],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.05921686,"threshold_uncertainty_score":0.4296504,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1263517822993334,"score_gpt":0.4622141423161643,"score_spread":0.3358623600168308,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}